Cosmo Pharmaceuticals SpA spin-off Cassiopea SpA, the Swiss-listed, dermatology-focused company that raised CHF175.6m ($180m) in an initial public offering (IPO) in early July this year, is set to begin Phase III trials with its lead product candidate, a first-in-class acne treatment, in October. Some analysts have forecast $350m in peak US sales for Winlevi.
"Our physician channel checks suggest possible rapid and widespread adoption, mostly as an integral part of the combination regimens typically...
Welcome to Scrip
Create an account to read this article
Already a subscriber?